| EX0693 FISH: NTRK1/2/3 GENE REARRANGEMENT ASSAY |
| Specimen: |
Submit formalin-fixed paraffin-embedded Tissue Block. Ship at room temperature. Tissue block must contain at least 10% tumor tissue. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| NA |
NA |
NA |
|
| Method: |
FISH |
| Comment: |
Samples received on holidays will be reported in the next schedule / next working day. |
| Report: |
Contact us to know the TAT. |
| Usage: |
Neurotrophic tropomyosin receptor kinase (NTRK) gene rearrangements have recently emerged as targets for cancer therapy. Gene rearrangements that involve NTRK1/2/3 can generate fusion oncoproteins that contain the kinase domains of TRKA/B/C, respectively. In NSCLC (Nonsmall cell lung cancer), NTRK fusions are estimated to occur at a frequency of approximately 0.1% to 1%. The TRK inhibitors namely, Larotrectinib (LOXO-101) and Entrectinib (RXDX-101) are oral tyrosine kinase inhibitors that have high selectivity and potency for TRKA, TRKB, and TRKC. This panel provides simultaneous analysis of NTRK1/2/3 gene rearrangements to identify TRK-inhibitor therapy in solid tumors. |
| Doctor Specialty: |
Oncologist |
| Disease: |
Cancer |
| Components: |
*NTRK1(1q21.3) *NTRK2 (9q21.3) *NTRK3 (15q25.3) |
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
CYTOGENETICS |
| Pre Test Information: |
A duly filled Chromosome & FISH analysis Requisition Form is mandatory. |
Reviews
There are no reviews yet.